

TIANJIN ZHONG XIN PHARMACEUTICAL GROUP CORPORATION LIMITED

(Company Registration No. 91120000103100784F)

(Incorporated in People's Republic of China)

RESOLUTIONS PASSED AT THE 5TH SUPERVISORY COMMITTEE MEETING FOR FY2021

The board of directors (the "Board") and every individual director of Tianjin Zhong Xin Pharmaceutical Group Corporation Limited (the "Company") hereby confirm that they will individually and collectively accept full responsibility for the accuracy of the information given in this announcement, and confirm, having made all reasonable enquiries, that to the best of their knowledge and belief, the facts stated in this announcement are fair and accurate in all material respects as at the date of this announcement, and that there are no material facts the omission of which would make any statement in this announcement misleading.

The Company had on 25 October 2021 duly convened its 5th supervisory committee (the "**Supervisory Committee**") meeting for the financial year ending 31 December 2021 ("**FY2021**") by means of telephone conference. The said meeting was convened in compliance with the Articles of Association of the Company, and the following resolutions were discussed and passed by 3 members out of the full Supervisory Committee of 3 members:

1. That, the appointment of Mr. Xing Jianhua (幸建华) as a member of the Supervisory Committee be approved.

As the term of office of Mr. Zhao Zhibin (赵智彬) as a Supervisor of the Company is expiring, the Company intends to appoint Mr. Xing Jianhua as Supervisor of the Company to replace Mr. Zhao Zhibin, and will be proposing this to the shareholders of the Company for approval at a general meeting of the Company.

Mr. Xing Jianhua, born in August 1971, holds a Bachelor's Degree in Engineering and a Master of Accounting Degree. From March 2014 to February 2018, he held concurrent positions as Deputy General Manager and Chief Accountant of CGNPC Uranium Resources Co., Ltd. (中广核铀业发展有限公司). From February 2018 to May 2021, he served as Person-in-charge of Finance of China Xiongan Group Co., Ltd. (中国雄安集团有限公司). Since May 2021, Mr. Xing has been appointed as Chief Financial Officer of Tianjin Pharmaceutical Holdings Co., Ltd. (天津市医药集团有限公司) ("**TPH**").

2. That, the proposed extension of time to perform the non-compete undertaking (details of which are as set out below) by the controlling shareholder of the Company, TPH, be approved.

TPH had previously undertaken that, in relation to the Company's sales business segment, TPH undertakes to transfer (either via share or asset sales) its subsidiaries that are in this segment to the Company or independent third parties by 31 December 2021, so as to ensure that TPH will no longer be in control of such subsidiaries. TPH now is requesting for an extension of time to fulfil the above undertaking by 31 December 2024 (the "**Proposed Extension**"). Please refer to the announcement dated 25 October 2021 made by the Company in relation to the Proposed Extension for further details.

The Supervisory Committee is of the view that the Proposed Extension is in compliance with the *Guideline No. 4 for the Supervision of Listed Companies – Commitments and Fulfillment*

of Commitments of the Actual Controllers, Shareholders, Affiliates and Acquirers of Listed Companies as Well as the Listed Companies (《上市公司监管指引第四号—上市公司实际控制人、股东、关联方、收购人以及上市公司承诺及履行》) issued by the China Securities Regulatory Commission, and the deliberation and decision-making procedures in relation to the Proposed Extension are in compliance with the provisions of relevant laws and regulations including the *Company Law of the People's Republic of China (《中华人民共和国公司法》)* and the *Listing Rules of Shanghai Stock Exchange (《上海证券交易所股票上市规则》)*, as well as the Articles of Association of the Company. The Proposed Extension will not be prejudicial to the interests of the Company and the minority shareholders of the Company.

The above resolutions No.1 and No.2 shall be tabled for shareholders' approval at a general meeting of the Company to be convened in due course.

By order of the Board

Jiao Yan
Secretary to the Board of Directors
25 October 2021